EvaluateMedTech™ Delivers One-Stop Source for MedTech Intelligence
LONDON AND BOSTON, Sept. 28, 2012 /CNW/ - EvaluatePharma, the premier source for life science sector analysis and consensus
forecasts, today announced the launch of EvaluateMedTech™, a new intelligence service focused on the medical device and
diagnostic sector. Powered by EvaluatePharma's proven platform and high
quality data, EvaluateMedTech™ allows companies, investment banks,
management consultancies and service providers to easily track and
benchmark the sector in a one-stop, up-to-date online platform.
"For more than a decade, our team has provided the global pharmaceutical
market with independent, clear and concise intelligence unrivaled in
the industry. We are pleased to now extend our analysis to the medical
device and diagnostic industry," said Dr. Jonathan de Pass, CEO of
EvaluateMedTech™ is designed to help those involved in the medtech
industry to compete effectively in the global market and increase
shareholder value and ROI. Its unique insights, derived from public
company information, equity analyst reports, regulatory approvals,
clinical trials, press releases and venture financing data, among other
sources, provide an easy way to derive business answers. It provides:
The first consensus view of the medtech industry including company
segment and product consensus sales forecasts to 2018.
The first database to model in detail sales from the devices that
comprise a company's reported segments and correlate those to rich data
sources and news.
Six integrated Devices@FDA databases for access to filings and
approvals, along with EU CE Mark news and Japan PDMA approvals.
A proprietary medtech portfolio database to track R&D and marketed
devices for a comprehensive device lifecycle picture.
As part of the new service, EvaluatePharma will release its first annual
EvaluateMedTech World Preview report at the 2012 AdvaMed conference in Boston on October 1, 2012. The complimentary report
provides top insights into the medtech sector, including the expected
performance of the industry through 2018. The report will be available
beginning Oct 2, 2012 at http://www.evaluatemedtech.com.
Since 1996, EvaluatePharma has been the premier source for life science
sector analysis, delivering exclusive, trusted commercial insight into
industry performance through its proprietary platform. EvaluatePharma
is staffed by a team of over 85 dedicated healthcare analysts employing
rigorous methodologies to collate, organize and deliver the
most-up-to-date commercial performance data available. An award winning
editorial team of journalists writing under the EP Vantage name support
EvaluatePharma's analysis. In October 2012, EvaluatePharma launches
its EvaluateMedTech™ service providing the first global consensus view
of the medical device and diagnostic industry. The EvaluatePharma
services enable the life science community to make sound business
decisions about value and opportunity. For more information please
SOURCE: EvaluatePharma Ltd
For further information: